Supreme Court Seeks Critical Data on NAT Testing Amid Push for Nationwide Blood Safety Mandate

In a significant development for public health jurisprudence, a bench of the Supreme Court of India , led by Chief Justice Surya Kant alongside Justices Joymalya Bagchi and Vipul M. Pancholi, has directed petitioners in a landmark Public Interest Litigation (PIL) to furnish detailed data on the costs and availability of Nucleic Acid Amplification Testing (NAT) in government hospitals across the country. The PIL, filed by the NGO Sarvesham Mangalam Foundation , urges the court to recognize the " Right to Safe Blood " as an intrinsic part of the fundamental right to life under Article 21 of the Constitution and to mandate NAT screening in all blood banks nationwide. This directive underscores the judiciary's pragmatic approach, balancing aspirational health rights against fiscal and infrastructural realities, with the matter now listed for further hearing on March 13 .

The case, titled Sarvesham Mangalam Foundation v. Union of India (W.P.(C) No. 184/2026), has spotlighted the vulnerabilities in India's blood transfusion system, particularly for patients with chronic conditions like Thalassemia who rely on frequent blood supplies. Counsel A. Velan , representing the petitioner, highlighted how current screening methods fall short, turning life-sustaining transfusions into potential "gambles with death." The Union Ministry of Health and Family Welfare , along with all States and Union Territories, have been arrayed as parties, signaling the petition's far-reaching implications for federal health policy.

Background of the PIL: A Cry for Constitutional Protection in Blood Safety

The PIL stems from deep-seated concerns over Transfusion Transmissible Infections (TTIs), including HIV, Hepatitis B (HBV), Hepatitis C (HCV), malaria, and syphilis. Filed under Article 32 , it seeks two primary reliefs: (1) a declaration that the right to safe, infection-free blood is embedded within Article 21's guarantee of life and personal liberty, and (2) directions for compulsory NAT implementation in every blood bank, public or private.

Thalassemia, an inherited blood disorder characterized by insufficient hemoglobin production, exemplifies the human cost. India bears one of the world's highest burdens, with over 10,000 patients requiring transfusions every 15-20 days to survive. The petition paints a grim picture: without advanced screening, these patients face recurrent risks of TTIs, exacerbating their plight. It invokes the state's duty to protect vulnerable populations, drawing parallels to landmark judgments expanding Article 21, such as Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996), which mandated emergency medical care as a fundamental right.

Regulatory context is crucial. Blood banks in India operate under the Drugs and Cosmetics Act, 1940 , and Rules, 1945, which currently mandate only Enzyme-Linked Immunosorbent Assay (ELISA) testing—a serological method less sensitive during the "window period" when infections are present but antibodies undetectable. The National AIDS Control Organisation (NACO) has recommended NAT since 2011 for high-risk settings, yet its adoption remains patchy, limited largely to Delhi's government hospitals. This disparity, the PIL argues, violates equality under Article 14 and the right to health.

The Science Behind NAT: Superior Detection for Window Period Risks

At the heart of the controversy is NAT, a molecular diagnostic technique that directly detects viral genetic material (DNA or RNA) in blood. Unlike ELISA, which relies on antibody responses (detectable only after 20-60 days post-infection), NAT identifies pathogens within 5-10 days—the critical window period responsible for most transfusion-related transmissions.

Petitioner's counsel emphasized NAT's superiority: "through NAT blood testing, a vast number of infections can be identified, as compared to the common method of ELISA testing." Studies cited in the PIL, including WHO guidelines, affirm NAT reduces TTI risk by over 90% in the window phase. Cost-wise, while NAT is pricier per unit (Rs. 500-1000 vs. ELISA's Rs. 200-300), bulk procurement and mini-pool testing (testing 6-24 units together) could slash expenses, making it viable even for resource-strapped facilities.

Yet, implementation hurdles persist: NAT requires sophisticated equipment like real-time PCR machines, trained technicians, and cold-chain logistics. Only about 5-10% of India's 5,000+ blood banks currently offer it, mostly private metros.

Highlighted Tragedies: Preventable Deaths Fueling the Litigation

The petition marshals harrowing incidents to underscore urgency:

  • In 2025 , at least six Thalassemia children at Satna District Hospital, Madhya Pradesh, tested HIV-positive post-transfusion.
  • Five children contracted HIV after transfusions at Sadar Hospital, Chaibasa, Jharkhand, also in 2025 .
  • In 2023 , fourteen children in Uttar Pradesh tested positive for hepatitis and HIV following transfusions at a medical college.

These "preventable tragedies," as described, expose systemic failures. The petitioner argues such lapses infringe Article 21, transforming blood banks from lifelines into hazards.

Court Hearing: CJI's Sharp Queries on Feasibility

During the hearing, the bench probed practicalities. Chief Justice Surya Kant queried cost-efficiency:

"Delhi can afford, in other states, who are struggling hard to even pay their employees, those who are unable to pay electricity charges, you want to put another burden on them?"

Counsel responded that costs would be "substantially less," but the CJI insisted on evidence:

"You do your homework and find out in how many state hospitals it is available, is it available Pan India or in a few states? or there are some states where it is not available at all... we don't know that, you will have to find out."

The court granted time for an affidavit detailing NAT costs and government hospital availability, ensuring economically weaker patients' access. This reflects judicial restraint, prioritizing data over directives.

Legal Arguments Anchored in Article 21: Expanding the Right to Health

The PIL's core contention—that safe blood is sine qua non for life—aligns with Article 21's evolution. From Maneka Gandhi (1978) broadening "personal liberty" to include dignity, to Parmanand Katara (1989) on road accident aid, the Court has iteratively incorporated health rights. Recent cases like Common Cause v. Union of India (2018) on living wills affirm state obligations for quality life.

Critically, mandating NAT could invoke the doctrine of " non-feasance to misfeasance ," holding states accountable for inadequate safeguards. However, fiscal federalism ( Article 246 ) tempers this: health is a state subject ( Entry 6, List II ), with Union coordination ( Entry 52-A ). The bench's concerns echo State of Punjab v. Ram Lubhaya Bagga (1998), weighing costs against rights.

Broader Legal Implications and Precedents

A favorable ruling could catalyze amendments to Drugs and Cosmetics Rules, aligning with global standards (e.g., FDA mandates NAT for HIV/HCV). It might spur NACO to enforce 100% NAT, funded via CSR or central schemes like Ayushman Bharat.

Precedently, it builds on Dr. Mukesh Kumar Saxena v. Union of India (mandating blood bank standards) and challenges like the 2012 Delhi HIV transfusion PIL. Success hinges on petitioner's affidavit proving affordability—perhaps via pooled procurement models successful in pilot states like Maharashtra.

Potential Impacts on Legal Practice and Public Health Policy

For legal professionals, this case revitalizes PIL practice in health law, offering opportunities in advisory roles for blood banks/NGOs, compliance audits, and federal litigation. Health lawyers may see surge in TTI compensation claims under tort law/consumer forums.

Policy-wise, nationwide NAT could avert thousands of infections annually (NACO estimates 1-2% TTI prevalence), saving Rs. 10,000 crore in treatment costs long-term. Yet, poorer states risk non-compliance, inviting contempt petitions. Private blood banks (80% of supply) face upgrades, potentially hiking costs but enabling premium safe-blood certifications.

Federally, it pressures Health Ministry for infrastructure grants, integrating with National Blood Policy 2002 revisions.

Looking Ahead: March 13 Hearing and Path Forward

With the bench granting leeway for data, March 13 looms pivotal. If feasibility is established, interim mandates for high-volume banks or Thalassemia centers could follow, paving for a seminal Article 21 pronouncement. Until then, the case exemplifies the judiciary's role as public health sentinel—cautious yet committed to elevating safe blood from aspiration to right.

This litigation not only spotlights transfusion perils but reaffirms Article 21's dynamism, compelling stakeholders to bridge rhetoric and reality in India's quest for universal health security.